Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
10
2017
accepted:
18
05
2018
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
17
9
2019
Statut:
epublish
Résumé
Liver cirrhosis mortality number has increased over the last decades. We aimed to estimate the liver cirrhosis mortality rate and its trends for the first time by sex, age, geographical distribution, and cause in Iran. Iranian Death Registration System, along with demographic (Complete and Summary Birth History, Maternal Age Cohort and Period methods) and statistical methods (Spatio-temporal and Gaussian process regression models) were used to address the incompleteness and misclassification and uncertainty of death registration system to estimate annual cirrhosis mortality rate. Percentages of deaths were proportionally redistributed into cirrhosis due to hepatitis B, C and alcohol use based on the data from the Global Burden of Disease (GBD) 2010 study. Liver cirrhosis mortality in elder patients was 12 times higher than that in younger patients at national level in 2015. Over the 26 years, liver cirrhosis mortality in males has increased more than that in females. Plus, the percentage of change in age adjusted mortality rate at provincial levels varied between decreases of 64.53% to nearly 17% increase. Mortality rate has increased until 2002 and then decreased until 2015.The province with highest mortality rate in 2015 has nearly two times greater rate compare to the lowest. More than 60% of liver cirrhosis mortality cases at national level are caused by hepatitis B and C infection. The rate of hepatitis B mortality is four times more than that from hepatitis C. This study demonstrated an increasing and then decreasing pattern in cirrhosis mortality that could be due to national vaccination of hepatitis B program. However monitoring, early detection and treatment of risk factors of cirrhosis, mainly in high risk age groups and regions are essential. Cirrhosis mortality could be diminished by using new non-invasive methods of cirrhosis screening, hepatitis B vaccination, definite treatment of hepatitis C.
Sections du résumé
BACKGROUND
Liver cirrhosis mortality number has increased over the last decades. We aimed to estimate the liver cirrhosis mortality rate and its trends for the first time by sex, age, geographical distribution, and cause in Iran.
METHOD
Iranian Death Registration System, along with demographic (Complete and Summary Birth History, Maternal Age Cohort and Period methods) and statistical methods (Spatio-temporal and Gaussian process regression models) were used to address the incompleteness and misclassification and uncertainty of death registration system to estimate annual cirrhosis mortality rate. Percentages of deaths were proportionally redistributed into cirrhosis due to hepatitis B, C and alcohol use based on the data from the Global Burden of Disease (GBD) 2010 study.
RESULTS
Liver cirrhosis mortality in elder patients was 12 times higher than that in younger patients at national level in 2015. Over the 26 years, liver cirrhosis mortality in males has increased more than that in females. Plus, the percentage of change in age adjusted mortality rate at provincial levels varied between decreases of 64.53% to nearly 17% increase. Mortality rate has increased until 2002 and then decreased until 2015.The province with highest mortality rate in 2015 has nearly two times greater rate compare to the lowest. More than 60% of liver cirrhosis mortality cases at national level are caused by hepatitis B and C infection. The rate of hepatitis B mortality is four times more than that from hepatitis C.
CONCLUSION
This study demonstrated an increasing and then decreasing pattern in cirrhosis mortality that could be due to national vaccination of hepatitis B program. However monitoring, early detection and treatment of risk factors of cirrhosis, mainly in high risk age groups and regions are essential. Cirrhosis mortality could be diminished by using new non-invasive methods of cirrhosis screening, hepatitis B vaccination, definite treatment of hepatitis C.
Identifiants
pubmed: 30645598
doi: 10.1371/journal.pone.0198449
pii: PONE-D-17-32628
pmc: PMC6333345
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0198449Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hepatology. 2013 Jul;58(1):21-30
pubmed: 23080403
J Gastrointestin Liver Dis. 2007 Dec;16(4):403-6
pubmed: 18193122
Curr Opin Gastroenterol. 2015 May;31(3):184-91
pubmed: 25850346
Arch Iran Med. 2014 Jan;17(1):7-15
pubmed: 24444059
J Natl Cancer Inst. 1993 Jul 7;85(13):1063-8
pubmed: 8515493
Arch Iran Med. 2014 Jan;17(1):28-33
pubmed: 24444062
Iran J Public Health. 2012;41(4):55-62
pubmed: 23113165
J Hepatol. 2013 Mar;58(3):593-608
pubmed: 23419824
Middle East J Dig Dis. 2016 Jan;8(1):5-18
pubmed: 26933476
Pathol Biol (Paris). 2010 Aug;58(4):273-7
pubmed: 20378277
Lancet Glob Health. 2017 May;5(5):e537-e544
pubmed: 28363513
J Korean Med Sci. 2016 Nov;31 Suppl 2:S121-S128
pubmed: 27775249
Lancet. 2008 Mar 8;371(9615):838-51
pubmed: 18328931
Eur J Epidemiol. 2000;16(11):1081
pubmed: 11421480
Eur J Epidemiol. 2004;19(9):861-9
pubmed: 15499896
Arch Iran Med. 2014 Mar;17(3):176-81
pubmed: 24621360
Popul Health Metr. 2012 Jan 06;10:1
pubmed: 22226226
Arch Iran Med. 2014 Mar;17(3):189-92
pubmed: 24621362
J Magn Reson Imaging. 2015 Jul;42(1):204-10
pubmed: 25223820
AJR Am J Roentgenol. 2009 Jul;193(1):14-27
pubmed: 19542391
East Mediterr Health J. 2005 Jan-Mar;11(1-2):62-7
pubmed: 16532672
Eur Addict Res. 2010;16(4):193-201
pubmed: 20606444
Ann Hepatol. 2011 Oct-Dec;10(4):556-8
pubmed: 21911898
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Bull World Health Organ. 2014 Sep 1;92(9):672-9
pubmed: 25378758
Hepat Mon. 2016 Apr 26;16(4):e35577
pubmed: 27257428
Arch Iran Med. 2017 Jan;20(1):2-11
pubmed: 28112524
JAMA. 2014 Aug 13;312(6):631-40
pubmed: 25117132
Addiction. 1997 Mar;92 Suppl 1:S33-S41
pubmed: 9167285
Transfusion. 2016 Jul;56(7):1891-8
pubmed: 27273657
Lancet Infect Dis. 2005 Sep;5(9):558-67
pubmed: 16122679
BMC Med. 2014 Sep 18;12:145
pubmed: 25242656
Middle East J Dig Dis. 2010 Jan;2(1):14-9
pubmed: 25197507
Hepatology. 2016 Dec;64(6):1969-1977
pubmed: 27301913
Iran J Public Health. 2015 Apr;44(4):512-21
pubmed: 26056670
Arch Iran Med. 2014 Jan;17(1):22-7
pubmed: 24444061